Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2014, Article ID 917981, 10 pages
http://dx.doi.org/10.1155/2014/917981
Research Article

Glucagon-Like Peptide-1 as Predictor of Body Mass Index and Dentate Gyrus Neurogenesis: Neuroplasticity and the Metabolic Milieu

1Department of Psychiatry & Behavioral Sciences, Division of Neuropsychopharmacology, State University of New York, Downstate Medical Center (SUNY DMC), Brooklyn, NY 11203, USA
2Downstate College of Medicine, SUNY DMC, Brooklyn, NY 11203, USA
3New York State Psychiatric Institute, New York, NY 10032, USA
4Division of Endocrinology, Department of Internal Medicine, SUNY DMC, Brooklyn, NY 11203, USA
5Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, NY 10032, USA
6Departments of Psychiatry and Pathology and Cell Biology, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
7Departments of Surgery and Internal Medicine, SUNY DMC, Brooklyn, NY 11203, USA

Received 5 July 2014; Revised 14 October 2014; Accepted 15 October 2014; Published 23 November 2014

Academic Editor: Lucas Pozzo-Miller

Copyright © 2014 Jeremy D. Coplan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. D. Kimura, H. A. Tissenbaum, Y. Liu, and G. Ruvkun, “Daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans,” Science, vol. 277, no. 5328, pp. 942–946, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Castro, J. Krumsiek, N. J. Lehrbach, S. A. Murfitt, E. A. Miska, and J. L. Griffin, “A study of Caenorhabditis elegans DAF-2 mutants by metabolomics and differential correlation networks,” Molecular BioSystems, vol. 9, no. 7, pp. 1632–1642, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. T. Murphy and P. J. Hu, “Insulin/insulin-like growth factor signaling in C. elegans,” WormBook: The Online Review of C. elegans Biology, pp. 1–43, 2013. View at Google Scholar
  4. A. Calixto, J. S. Jara, and F. A. Court, “Diapause formation and downregulation of insulin-like signaling via DAF-16/FOXO delays axonal degeneration and neuronal loss,” PLoS Genetics, vol. 8, no. 12, Article ID e1003141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Mortensen, L. L. Christensen, J. J. Holst, and C. Orskov, “GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine,” Regulatory Peptides, vol. 114, no. 2-3, pp. 189–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. D. Turton, D. O'Shea, I. Gunn et al., “A role for glucagon-like peptide-1 in the central regulation of feeding,” Nature, vol. 379, no. 6560, pp. 69–72, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. K. A. Scott and T. H. Moran, “The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 293, no. 3, pp. R983–R987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Harkavyi and P. S. Whitton, “Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection,” British Journal of Pharmacology, vol. 159, no. 3, pp. 495–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. T. D. Perera, D. Lu, L. Thirumangalakudi et al., “Correlations between hippocampal neurogenesis and metabolic indices in adult nonhuman primates,” Neural Plasticity, vol. 2011, Article ID 875307, 6 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. D. Coplan, H. M. Fathy, C. G. Abdallah et al., “Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight,” NeuroImage: Clinical, vol. 4, pp. 326–335, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Kaufman, M. A. Banerji, I. Shorman et al., “Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques,” Diabetes, vol. 56, no. 5, pp. 1382–1386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Jackowski, T. D. Perera, C. G. Abdallah et al., “Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates,” Psychiatry Research: Neuroimaging, vol. 192, no. 1, pp. 37–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. L. Fulton, V. Panthangi, W. Reiner et al., “Cisternal CSF 5H1AA inversely predicts hippocampal volume in nonhuman primates (NHP): impact of early life stress (ELS) on serotonin function,” Biological Psychiatry, vol. 75, supplement 1, no. 9, pp. 312S–313S, 2014. View at Google Scholar
  14. J. D. Coplan, H. M. Fathy, A. Jackowski et al., “Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene,” Frontiers in Behavioral Neuroscience, vol. 8, article 342, 2014. View at Publisher · View at Google Scholar
  15. J. D. Coplan, C. G. Abdallah, C. Y. Tang et al., “The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates,” Neuroscience Letters, vol. 480, no. 2, pp. 93–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Sleddering, L. E. H. Bakker, L. G. M. Janssen, A. E. Meinders, and I. M. Jazet, “Higher insulin and glucagon-like peptide-1 (GLP-1) levels in healthy, young South Asians as compared to Caucasians during an oral glucose tolerance test,” Metabolism: Clinical and Experimental, vol. 63, no. 2, pp. 226–232, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. K. M. Flegal, D. Carroll, B. K. Kit, and C. L. Ogden, “Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010,” The Journal of the American Medical Association, vol. 307, no. 5, pp. 491–497, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” The Journal of the American Medical Association, vol. 289, no. 1, pp. 76–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. R. C. Turner, R. R. Holman, D. Matthews, T. D. R. Hockaday, and J. Peto, “Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations,” Metabolism, vol. 28, no. 11, pp. 1086–1096, 1979. View at Publisher · View at Google Scholar · View at Scopus
  20. J. D. Coplan, M. Altemus, S. J. Mathew et al., “Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand,” CNS Spectrums, vol. 10, no. 7, pp. 530–536, 2005. View at Google Scholar · View at Scopus
  21. T. D. Perera, J. D. Coplan, S. H. Lisanby et al., “Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates,” The Journal of Neuroscience, vol. 27, no. 18, pp. 4894–4901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Cohen, “Eta-squared and partial eta-squared in fixed factor ANOVA designs,” Educational and Psychological Measurement, vol. 33, no. 1, pp. 107–112, 1973. View at Publisher · View at Google Scholar
  23. S. B. Pierce, M. Costa, R. Wisotzkey et al., “Regulation of DAF-2 receptor signaling by human insulin and ins-1, a member of the unusually large and diverse C. elegans insulin gene family,” Genes and Development, vol. 15, no. 6, pp. 672–686, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Isacson, E. Nielsen, K. Dannaeus et al., “The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test,” European Journal of Pharmacology, vol. 650, no. 1, pp. 249–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Salcedo, D. Tweedie, Y. Li, and N. H. Greig, “Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders,” British Journal of Pharmacology, vol. 166, no. 5, pp. 1586–1599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Nakagawa, A. Tsuchida, Y. Itakura et al., “Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice,” Diabetes, vol. 49, no. 3, pp. 436–444, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. J. A. Pospisilik, S. G. Stafford, H.-U. Demuth et al., “Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats,” Diabetes, vol. 51, no. 4, pp. 943–950, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. D. E. Moller, “New drug targets for type 2 diabetes and the metabolic syndrome,” Nature, vol. 414, no. 6865, pp. 821–827, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. Meier, A. Gethmann, O. Götze et al., “Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans,” Diabetologia, vol. 49, no. 3, pp. 452–458, 2006. View at Publisher · View at Google Scholar · View at Scopus